<DOC>
	<DOC>NCT01477632</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to determine the extent of bioavailability of two low dose estradiol/norethisterone acetate (NETA) preparations with a marketed estradiol/norethisterone acetate (NETA) preparation.</brief_summary>
	<brief_title>Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy Postmenopausal Caucasian race Smoking (up to 5 cig./per day) is allowed Good state of health: evidenced by medical history, physical examination including gynecological examination, results of laboratory examination Known or suspected allergy to trial products or related products Previous participation in this trial Previous estrogen and/or progestin hormone replacement therapy Known, suspected or history of breast cancer Systolic blood pressure (BP) at least 160 mm Hg and/or diastolic BP at least 100 mm Hg, currently treated or untreated Body Mass Index (BMI) above 35.0 kg/m^2</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>